338 related articles for article (PubMed ID: 25165165)
1. Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans.
Baden LR; Liu J; Li H; Johnson JA; Walsh SR; Kleinjan JA; Engelson BA; Peter L; Abbink P; Milner DA; Golden KL; Viani KL; Stachler MD; Chen BJ; Pau MG; Weijtens M; Carey BR; Miller CA; Swann EM; Wolff M; Loblein H; Seaman MS; Dolin R; Barouch DH
J Infect Dis; 2015 Feb; 211(4):518-28. PubMed ID: 25165165
[TBL] [Abstract][Full Text] [Related]
2. Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001).
Barouch DH; Liu J; Peter L; Abbink P; Iampietro MJ; Cheung A; Alter G; Chung A; Dugast AS; Frahm N; McElrath MJ; Wenschuh H; Reimer U; Seaman MS; Pau MG; Weijtens M; Goudsmit J; Walsh SR; Dolin R; Baden LR
J Infect Dis; 2013 Jan; 207(2):248-56. PubMed ID: 23125443
[TBL] [Abstract][Full Text] [Related]
3. Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22).
Stephenson KE; Wegmann F; Tomaka F; Walsh SR; Tan CS; Lavreys L; Ansel JL; Kanjilal DG; Jaegle K; Nkolola JP; Peter L; Fogel R; Bradshaw C; Tyler A; Makoni T; Howe L; Quijada D; Chandrashekar A; Bondzie EA; Borducchi EN; Yanosick KE; Hendriks J; Nijs S; Truyers C; Tolboom J; Zahn RC; Seaman MS; Alter G; Stieh DJ; Pau MG; Schuitemaker H; Barouch DH
Lancet HIV; 2020 Jun; 7(6):e410-e421. PubMed ID: 32078815
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector.
Catanzaro AT; Koup RA; Roederer M; Bailer RT; Enama ME; Moodie Z; Gu L; Martin JE; Novik L; Chakrabarti BK; Butman BT; Gall JG; King CR; Andrews CA; Sheets R; Gomez PL; Mascola JR; Nabel GJ; Graham BS;
J Infect Dis; 2006 Dec; 194(12):1638-49. PubMed ID: 17109335
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study.
Baden LR; Stieh DJ; Sarnecki M; Walsh SR; Tomaras GD; Kublin JG; McElrath MJ; Alter G; Ferrari G; Montefiori D; Mann P; Nijs S; Callewaert K; Goepfert P; Edupuganti S; Karita E; Langedijk JP; Wegmann F; Corey L; Pau MG; Barouch DH; Schuitemaker H; Tomaka F;
Lancet HIV; 2020 Oct; 7(10):e688-e698. PubMed ID: 33010242
[TBL] [Abstract][Full Text] [Related]
6. First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001).
Baden LR; Walsh SR; Seaman MS; Tucker RP; Krause KH; Patel A; Johnson JA; Kleinjan J; Yanosick KE; Perry J; Zablowsky E; Abbink P; Peter L; Iampietro MJ; Cheung A; Pau MG; Weijtens M; Goudsmit J; Swann E; Wolff M; Loblein H; Dolin R; Barouch DH
J Infect Dis; 2013 Jan; 207(2):240-7. PubMed ID: 23125444
[TBL] [Abstract][Full Text] [Related]
7. Robust antigen-specific humoral immune responses to sublingually delivered adenoviral vectors encoding HIV-1 Env: association with mucoadhesion and efficient penetration of the sublingual barrier.
Domm W; Brooks L; Chung HL; Feng C; Bowers WJ; Watson G; McGrath JL; Dewhurst S
Vaccine; 2011 Sep; 29(40):7080-9. PubMed ID: 21801777
[TBL] [Abstract][Full Text] [Related]
8. A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.
Keefer MC; Gilmour J; Hayes P; Gill D; Kopycinski J; Cheeseman H; Cashin-Cox M; Naarding M; Clark L; Fernandez N; Bunce CA; Hay CM; Welsh S; Komaroff W; Hachaambwa L; Tarragona-Fiol T; Sayeed E; Zachariah D; Ackland J; Loughran K; Barin B; Cormier E; Cox JH; Fast P; Excler JL
PLoS One; 2012; 7(8):e41936. PubMed ID: 22870265
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).
Barouch DH; Tomaka FL; Wegmann F; Stieh DJ; Alter G; Robb ML; Michael NL; Peter L; Nkolola JP; Borducchi EN; Chandrashekar A; Jetton D; Stephenson KE; Li W; Korber B; Tomaras GD; Montefiori DC; Gray G; Frahm N; McElrath MJ; Baden L; Johnson J; Hutter J; Swann E; Karita E; Kibuuka H; Mpendo J; Garrett N; Mngadi K; Chinyenze K; Priddy F; Lazarus E; Laher F; Nitayapan S; Pitisuttithum P; Bart S; Campbell T; Feldman R; Lucksinger G; Borremans C; Callewaert K; Roten R; Sadoff J; Scheppler L; Weijtens M; Feddes-de Boer K; van Manen D; Vreugdenhil J; Zahn R; Lavreys L; Nijs S; Tolboom J; Hendriks J; Euler Z; Pau MG; Schuitemaker H
Lancet; 2018 Jul; 392(10143):232-243. PubMed ID: 30047376
[TBL] [Abstract][Full Text] [Related]
10. Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre Study.
Cosgrove CA; Lacey CJ; Cope AV; Bartolf A; Morris G; Yan C; Baden S; Cole T; Carter D; Brodnicki E; Shen X; Joseph S; DeRosa SC; Peng L; Yu X; Ferrari G; Seaman M; Montefiori DC; Frahm N; Tomaras GD; Stöhr W; McCormack S; Shattock RJ
PLoS One; 2016; 11(5):e0152038. PubMed ID: 27159166
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial.
Baden LR; Karita E; Mutua G; Bekker LG; Gray G; Page-Shipp L; Walsh SR; Nyombayire J; Anzala O; Roux S; Laher F; Innes C; Seaman MS; Cohen YZ; Peter L; Frahm N; McElrath MJ; Hayes P; Swann E; Grunenberg N; Grazia-Pau M; Weijtens M; Sadoff J; Dally L; Lombardo A; Gilmour J; Cox J; Dolin R; Fast P; Barouch DH; Laufer DS;
Ann Intern Med; 2016 Mar; 164(5):313-22. PubMed ID: 26833336
[TBL] [Abstract][Full Text] [Related]
12. Mucosal Immunization with Newcastle Disease Virus Vector Coexpressing HIV-1 Env and Gag Proteins Elicits Potent Serum, Mucosal, and Cellular Immune Responses That Protect against Vaccinia Virus Env and Gag Challenges.
Khattar SK; Manoharan V; Bhattarai B; LaBranche CC; Montefiori DC; Samal SK
mBio; 2015 Jul; 6(4):e01005. PubMed ID: 26199332
[TBL] [Abstract][Full Text] [Related]
13. Mucosal trafficking of vector-specific CD4+ T lymphocytes following vaccination of rhesus monkeys with adenovirus serotype 5.
Masek-Hammerman K; Li H; Liu J; Abbink P; La Porte A; O'Brien KL; Whitney JB; Carville A; Mansfield KG; Barouch DH
J Virol; 2010 Oct; 84(19):9810-6. PubMed ID: 20686023
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of humoral, mucosal, and cellular immune responses following co-immunization of HIV-1 Gag and Env proteins expressed by Newcastle disease virus.
Khattar SK; Palaniyandi S; Samal S; LaBranche CC; Montefiori DC; Zhu X; Samal SK
Hum Vaccin Immunother; 2015; 11(2):504-15. PubMed ID: 25695657
[TBL] [Abstract][Full Text] [Related]
15. Preexisting memory CD4+ T cells contribute to the primary response in an HIV-1 vaccine trial.
Campion SL; Brenna E; Thomson E; Fischer W; Ladell K; McLaren JE; Price DA; Frahm N; McElrath JM; Cohen KW; Maenza JR; Walsh SR; Baden LR; Haynes BF; Korber B; Borrow P; McMichael AJ
J Clin Invest; 2021 Dec; 131(23):. PubMed ID: 34850742
[TBL] [Abstract][Full Text] [Related]
16. Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques.
Shen X; Bogers WM; Yates NL; Ferrari G; Dey AK; Williams WT; Jaeger FH; Wiehe K; Sawant S; Alam SM; LaBranche CC; Montefiori DC; Martin L; Srivastava I; Heeney J; Barnett SW; Tomaras GD
J Virol; 2017 Oct; 91(19):. PubMed ID: 28490585
[TBL] [Abstract][Full Text] [Related]
17. First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002).
Baden LR; Walsh SR; Seaman MS; Johnson JA; Tucker RP; Kleinjan JA; Gothing JA; Engelson BA; Carey BR; Oza A; Bajimaya S; Peter L; Bleckwehl C; Abbink P; Pau MG; Weijtens M; Kunchai M; Swann EM; Wolff M; Dolin R; Barouch DH
J Infect Dis; 2014 Oct; 210(7):1052-61. PubMed ID: 24719474
[TBL] [Abstract][Full Text] [Related]
18. Delivery of human immunodeficiency virus vaccine vectors to the intestine induces enhanced mucosal cellular immunity.
Wang L; Cheng C; Ko SY; Kong WP; Kanekiyo M; Einfeld D; Schwartz RM; King CR; Gall JG; Nabel GJ
J Virol; 2009 Jul; 83(14):7166-75. PubMed ID: 19420074
[TBL] [Abstract][Full Text] [Related]
19. Enhanced induction of intestinal cellular immunity by oral priming with enteric adenovirus 41 vectors.
Ko SY; Cheng C; Kong WP; Wang L; Kanekiyo M; Einfeld D; King CR; Gall JG; Nabel GJ
J Virol; 2009 Jan; 83(2):748-56. PubMed ID: 18987146
[TBL] [Abstract][Full Text] [Related]
20. Intradermal HIV-1 DNA Immunization Using Needle-Free Zetajet Injection Followed by HIV-Modified Vaccinia Virus Ankara Vaccination Is Safe and Immunogenic in Mozambican Young Adults: A Phase I Randomized Controlled Trial.
Viegas EO; Tembe N; Nilsson C; Meggi B; Maueia C; Augusto O; Stout R; Scarlatti G; Ferrari G; Earl PL; Wahren B; Andersson S; Robb ML; Osman N; Biberfeld G; Jani I; Sandström E
AIDS Res Hum Retroviruses; 2018 Feb; 34(2):193-205. PubMed ID: 28969431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
